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Breast	 cancer	 (BC)	 is	 the	most	 common	 tumour	 in	women	 and	 one	 of	 the	most	
important	causes	of	cancer	death	worldwide.	Radiation	therapy	(RT)	is	widely	used	
for	BC	treatment.	Some	proteins	have	been	identified	as	prognostic	factors	for	BC	




other	 variables	 related	 to	 patient	 characteristics	 and	 tumour	 biology.	A	 group	of	
20	BC	patients	treated	with	RT	were	recruited.	MMP	and	TIMP	serum	levels	were	












ease	 at	 the	 inter‐	 and	 intra‐tumour	 level,	which	 is	 relevant	 to	 the	
prognosis	and	therapy	of	the	disease.2	The	type	of	BC,	its	location	
and	other	factors	(differentiation	grade,	size,	presence	of	different	
proteins—Ki67,	 p53,	 E‐cadherin—sentinel	 lymph	 node,	 patient	 age	
and	response	to	treatment)	are	also	relevant	to	the	prognosis.3
Breast	cancer	can	be	classified	according	to	location	(in	situ	and	

























biopsy	 do	 not	 require	 axillary	 lymph	 node	 dissection.15	 Age	 and	
menopausal	 status	 are	 another	 factor	 to	 consider	 in	 BC	 develop‐



















Matrix	 metalloproteases	 (MMPs)	 are	 a	 family	 of	 enzymes	 that	
differ	 in	 their	 structure,	 substrate	 specificity,	 sequence	 homology,	














but	 they	 also	 have	 biological	 activities	 that	 are	 independent	 of	
MMPs	including	cell	growth	and	differentiation,	angiogenesis,	apop‐
tosis	and	synaptic	plasticity.26	The	four	TIMPs	described	in	humans	
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2  | MATERIAL S AND METHODS
2.1 | Recruitment and characteristics of patients
This	pilot	study	was	carried	out	in	20	patients	with	BC	from	the	San	
Cecilio	University	Hospital	in	Granada.	These	patients	were	treated	
with	 either	 hypofractionated	 RT	 (16	 sessions,	 2.65	Gy/session)	 or	






was	 taken	at	RT	termination,	usually	on	the	 last	day	of	 treatment.	
Measurement	of	protein	levels	was	done	after	the	patients	had	re‐
ceived	approximately	similar	doses;	therefore,	it	is	unlikely	that	the	




RT,	 42.4	 and	 50	 Gy	 were	 administered	 for	 hypofractionated	 and	












ing	 to	 the	different	variables	 studied,	 including	patient‐dependent	
variables	 (age	 and	menopausal	 status),	 tumour	 biology‐dependent	




detail	 the	variables	studied,	 the	population	 (n)	and	the	percentage	
compared	with	total	population.	The	6‐month	BC	recurrence	is	also	
shown.




‐12,	 ‐13,	TIMP‐1,	 ‐2,	 ‐3	and	 ‐4),	according	 to	 the	protocols	provided	




used	were	 serum	aliquots	 obtained	 from	 the	 stored	 blood	 samples.	
































































TIMPs	before	 (Figure	2A),	during	 (Figure	2B)	and	after	 (Figure	2C)	
RT.	A	positive	correlation	was	found	between	the	levels	of	MMPs	at	
all	times	over	the	treatment,	being	this	correlation	stronger	with	RT.	
Nevertheless,	 positive	 and	 negative	 correlations	 have	 been	 found	
as	a	function	of	patient	treatment	time,	with	an	increase	in	negative	
correlations	for	TIMP‐1	and	‐3	with	RT.
3.3 | MMP and TIMP serum levels by variables
The	 correlation	 between	 serum	 levels	 of	 all	MMPs	 and	 TIMPs	 de‐
tected	 and	 the	 different	 variables	 was	 investigated,	 including	 pa‐
tient‐dependent	 variables	 (age	 and	 menopausal	 status),	 tumour	
biology‐dependent	variables	 (classification	based	on	hormones,	dif‐








serum	 levels	 of	MMPs	 and	TIMPs	before,	 during	 and	 after	RT	 and	
the	patient‐dependent	variables	(Figure	3A)	and	tumour	biology‐de‐
pendent	 variables	 (Figure	 3B	 and	 3).	 The	 results	 showed	 that	 only	
MMP‐3	 and	 TIMP‐4	 levels	 were	 statistically	 significant	 for	 some	
variables.	 Figure	 3A	 shows	 the	 correlation	 between	MMP‐3	 levels	
and	menopausal	status	of	the	patient.	 In	general,	this	protein	 levels	
were	higher	in	post‐menopausal	patients,	but	it	is	worth	noting	that	






≤50	y 10 50 9 1
>50 y 10 50 8 2
Menopausal	status
Pre‐menopausal 10 50 9 1
Menopausal 6 30 5 1
Post‐menopausal 4 20 3 1
Type	of	carcinoma
Invasive	ductal 19 95 16 3
Invasive	lobular 1 5 1 0
Tumour	classification	(ER,	PR,	HER2)
Hormone‐negative 2 10 1 1
Hormone‐positive 18 90 16 2
Differentiation	grade
Grade	I 9 45 8 1
Grade	II 7 35 6 1
Grade	III 4 20 3 1
E‐cadherin
Positive 16 80 14 2
Negative 4 20 3 1
p53
Positive 3 15 2 1
Negative 17 85 15 2
Ki67
<20% 15 75 13 2
≥20% 5 25 4 1
Sentinel	lymph	node
Yes 12 60 11 1
No 8 40 6 2
RT	regimen
Conventional 7 35 6 1
Hypofractionated 13 65 11 2
Lymph	node	RT
Yes 9 45 7 2
No 11 55 10 1
RT	toxicity
No 2 10 2 0
Hyperpigmentation 1 5 1 0
Erythema 12 60 10 2
Radiodermitis 5 25 4 1
Chemotherapy
Yes 11 55 9 2
No 9 45 8 1
Recurrence
Healthy 17 85   
Sick 3 15   
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for	 each	 group	 of	 patients	 (pre‐menopausal	 and	 post‐menopausal),	
the	levels	are	higher	at	a	different	time	of	the	treatment.	Figure	3B	
shows	the	correlation	between	MMP‐3	levels	and	tumour	classifica‐
tion,	 differentiation	 grade	 and	 E‐cadherin	 presence.	MMP‐3	 levels	
increased	in	patients	with	hormone‐positive	tumours	compared	with	
those	 with	 hormone‐negative	 tumours,	 having	 an	 increase	 in	 both	
groups	 throughout	 the	 treatment	with	RT.	Considering	 tumour	 dif‐
ferentiation	degree,	MMP‐3	levels	were	higher	after	RT	in	grade	I	and	
III	tumours.	However,	in	grade	II	tumours,	protein	levels	were	higher	













positive	tumours;	but	 it	 is	noteworthy	the	 large	 increase	 in	TIMP‐4	





TIMP‐1	 and	 ‐3	 levels	were	 found	 to	 be	 statistically	 significant	 for	
some	of	 the	variables.	Figure	4A	and	4	show	a	statistically	signifi‐
cant	correlation	between	MMP‐9	and	TIMP‐3	levels	with	the	type	
of	 radiation	 toxicity.	 MMP‐9	 levels	 were	 much	 higher	 in	 patients	
with	erythema,	showing	this	group	a	slight	increase	throughout	the	
treatment.	 Moreover,	 MMP‐9	 levels	 in	 patients	 with	 radiodermi‐
tis	were	much	higher	during	RT	than	before	or	after	RT.	However,	






3.4 | Comparison of MMP and TIMP serum levels, 












after	 RT	 in	 healthy	 patients.	 However,	 TIMP‐3	 levels	 (Figure	 5H)	








RT	 is	 a	 highly	 targeted	 and	 effective	 treatment	 modality	 for	





chronic	 (long‐term)	 and	 skin	 toxicity	 is	 the	most	 common	adverse	
effect	in	patients	with	BC.35
Little	research	has	documented	the	effect	of	RT	on	MMPs	and	
their	 tissue	 inhibitor	 expression	 in	 patients.	 Some	 authors	 have	












findings	 revealed	 a	 statistically	 significant	 decrease	 in	TIMP‐1	 and	
‐3	 serum	 levels	 with	 RT	 (Figure	 1).	 This	 could	 be	 associated	 with	
the	 increase	of	some	MMPs	analysed	 in	this	work.	 In	this	sense,	 it	
is	 important	 to	consider	 that	TIMPs	are	not	only	 involved	 in	MMP	
inhibition	 but	 also	 in	 different	 signalling	 pathways.	 Some	 authors	
have	described	that	TIMP‐1	stimulates	cancer	invasion	by	inhibiting	
apoptosis,	promoting	tumour	cell	growth	and	regulating	angiogene‐
sis	 in	metastatic	BC.37,38	A	 relationship	between	high	serum	 levels	
of	TIMP‐1	and	poor	prognosis	in	patients	with	BC	has	also	been	re‐
ported.39	Some	studies	have	documented	a	correlation	between	low	






sample	 size.	 To	mitigate	 this	 limitation,	we	 have	 searched	 differ‐
ent	database	for	similar	results.	Only	the	work	by	Tanic	et	al	(GEO	
database)	in	biopsies	from	non‐inflammatory	locally	advanced	pa‐
tients	with	 BC	 reported	 no	 changes	 in	MMP	 or	 TIMP	 levels	 be‐
tween	the	pre‐	(n	=	5)	and	post‐RT	(n	=	5)	group	(Figure	S1).	The	few	
pre‐	and	post‐RT–matched	sample	number	could	explain	 the	 lack	












Our	 results	 show	 a	 correlation	 between	 MMP‐3	 levels	 and	
menopausal	 status,	 tumour	 classification,	 differentiation	 degree	
and	E‐cadherin	presence	 (Figure	3).	Several	parameters	have	been	
investigated	 as	 prognostic	 predictors	 of	 BC,	 such	 as	 lymph	 node	
status,	 tumour	 size,	 histologic	 type,	 tumour	 grade,	 hormonal	 re‐











F I G U R E  2  Correlation	between	the	serum	levels	of	MMPs	and	TIMPs	before	(A),	during	(B)	and	after	(C)	RT.	The	range	of	colours	
represents	the	different	values	of	rho	(ρ):	positive	correlation	(0	<	ρ	<	1),	negative	correlation	(−1	<	ρ	<	0)	and	no	correlation	(ρ	=	0)






has	 also	 been	 confirmed.51	 Nevertheless,	 little	 is	 known	 about	
TIMP‐4.







Our	 results	 suggest	 that	 MMP‐9	 and	 TIMP‐3	 levels	 could	 be	
predictive	of	RT	toxicity,	particularly,	of	acute	effects	such	as	ery‐
thema	and	radiodermitis.	Some	authors	have	described	MMP	levels	
alterations	 in	 cancer	 following	 single	 and	 fractionated	 radiation	 in	
vivo.	Some	authors	found	statistically	increased	levels	of	MMP‐2,	‐3,	
‐9	and	‐14	in	the	colon	of	rats	irradiated	with	a	single	dose	of	10	Gy.	
MMP‐2	has	usually	been	 involved	 in	gastrointestinal	 toxicity	 after	




Matrix	 metalloproteases	 and	 TIMP	 serum	 level	 changes	 are	
associated	 with	 normal	 cells	 being	 adversely	 affected	 by	 RT	
(Figure	4).	We	should	consider	that	these	MMPs	are	produced	by	
both	tumour	and	normal	cells.	RT	could	have	promoted	an	increase	
in	protein	 levels	 in	cells	 from	healthy	 tissue	 located	 in	 the	 treat‐
ment	area,	and	therefore,	 they	would	also	be	 involved	 in	the	re‐
sponse	to	RT,	particularly	in	the	acute	response.	The	involvement	
of	MMPs	 in	 the	occurrence	of	 late	manifestations	of	RT	such	as	
radiation‐induced	fibrosis	cannot	be	ruled	out.	This	has	not	been	
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F I G U R E  4  Serum	levels	of	MMPs	and	TIMPs	before,	during	and	after	RT	based	on	RT‐related	variables	(A,	B	and	C).	Only	the	statistically	
significant	variables	are	represented.	(A)	MMP‐9	levels	in	relation	to	radiation	toxicity.	(B)	TIMP‐1	levels	in	relation	to	lymph	node	
radiotherapy.	(C)	TIMP‐3	levels	in	relation	to	radiation	toxicity.	Values	are	presented	as	median	±	SD	(error	bars);	*	P	<	.05
F I G U R E  5  Serum	levels	of	MMPs	and	TIMPs	before	and	after	RT	in	relation	to	the	six‐month	recurrence.	Values	are	presented	as	
median	±	SD	(error	bars);	*	P	<	.05	and	**	P	<	.01













involvement,	 Ki67	 percentage	 and	 E‐cadherin	 protein	 presence	
(Figure	3),	which	suggest	a	potential	use	of	these	TIMPs	as	biomark‐
ers	of	prognosis	and	response	to	RT.	A	tumour	is	clinically	radiore‐
sistant	when	 irradiation	 in	unable	 to	 reduce	 its	volume	or	when	a	
recurrence	 takes	 place	 after	 a	 possible	 regression.	 Thus,	 it	would	
be	of	great	interest	to	identify	biomarkers	predictive	of	response	to	
RT.	In	this	sense,	our	results	show	higher	levels	of	most	of	proteins	
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